abstract: We report a case of a cervical carotid artery @entity2849 with contralateral severe @entity850 , treated using a covered stent. A 79-year-old @entity1 admitted for a @entity438 presented a pulsatile mass on the right side of his neck and lower @entity129 after misinsertion of a central venous line into the right carotid artery. MRI revealed a huge @entity439 (30 mm 25 mm) in the right common carotid artery (CCA). We planned an aneurysmectomy and CCA interposition with a vascular graft. However the @entity439 continued to expand. We considered that it was difficult to expose the internal carotid artery (ICA) by a direct surgical technique, and therefore carried out placement of a covered stent over the orifice of the @entity439 using an endovascular surgical technique. Following placement of the covered stent, subsequent contrast-enhanced CT revealed leakage of contrast material into the @entity439 . An additional bare stent was placed into the proximal end of the covered stent at 15 days after the initial treatment. Angiography demonstrated no leakage of the contrast material. Following the second treatment, the pulsatile mass was reduced in size. Lower @entity129 remained but had slightly improved. We described the case of a huge cervical @entity1914 that was successfully treated using a covered stent.

title: [Case of a @entity438 with contralateral severe XXXX treated using a covered stent].

entities_list: @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial nerve palsy']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['thrombosed aneurysm', 'aneurysm']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity1914 :: ('MESH:D020212', 'Disease') :: ['carotid pseudoaneurysm']

entities_list: @entity2849 :: ('MESH:D017541', 'Disease') :: ['pseudoaneurysm']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['splenic artery aneurysm']

answer: @entity850 :: (MESH:D003251,Disease) :: ['stenosis']


abstract: AIMS: The aim of this study was to compare the anti-inflammatory effect of proteoglycan (PG) with that of @entity1420 (P) in the cultured fibroblasts from @entity1 uterine cervix. MAIN METHODS: After obtaining informed consent, the cervix was collected from normal @entity1 undergoing total hysterectomy. The cervix was cultured until fibroblasts proliferated and had grown to confluence, then, the fibroblasts were stimulated by lipopolysaccharide (LPS) with or without PG, P and a combination of both; they were cultured for 24-48 h. The anti-inflammatory effects of PG and P were evaluated by the suppression of @entity650 or @entity687 secretion. The expression of the @entity650 or @entity687 gene and the expression of their protein were determined by real-time PCR, and ELISA, respectively. Activation of Toll-like receptor ( @entity2939 was evaluated by Western blotting. KEY FINDINGS: LPS markedly enhanced gene and protein expression of @entity650 and @entity687 in @entity1 uterine cervical fibroblasts. The up-regulation of the @entity650 or @entity687 gene and protein expression by LPS was significantly suppressed with PG, P and a combination of both. Western blotting revealed that combination of PG and P showed more potent inhibition on LPS-stimulated @entity2939 induction than that seen by each. SIGNIFICANCE: This study showed that both PG and P have an inhibitory effect on LPS-induced @entity32 . This anti-inflammatory effect of PG and P was augmented by co-administration of both, suggesting for the first time that PG has an anti-inflammatory effect on @entity1 uterine cervical fibroblasts.

title: Anti-inflammatory effect of proteoglycan and XXXX on @entity1 uterine cervical fibroblasts.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

answer: @entity1420 :: (MESH:D011374,Chemical) :: ['progesterone']


abstract: UNASSIGNED: It has been reported from cities in Central Europe that clinical cases of @entity235 @entity743 are most frequent in spring time, despite the fact that the peak activity of Dermacentor reticulatus (the vector of @entity743 ) is during autumn. The present study was initiated to evaluate the seasonal distribution of @entity14991 -infected D. reticulatus ticks in this context. In two habitats of Budapest 852 D. reticulatus adults were collected between August, 2014 and June, 2015. Among the molecularly analysed 413 ticks 8.2% were PCR positive for piroplasms. Both formerly reported 18S rDNA genotypes of @entity14991 : ("A" and "B") were identified. In habitat-1 @entity14991 -infected ticks were detected only in spring. Similarly, in habitat-2 @entity14991 -infected ticks occurred significantly more frequently during winter and spring than in the autumn (24.6% vs. 1.4%), and their monthly distribution showed significant negative correlation with tick size. The prevalence of infected ticks was the highest (43.5%) in late February. In addition, a month-dependent time-shift was noted in the appearance of the two @entity14991 18S rDNA genotypes: the less pathogenic "A" predominating earlier, and the more pathogenic "B" later. It is known from literature that D. reticulatus individuals that moult to adult in the spring are smaller in size. Thus, the above results suggest that in urban habitats the occurrence of @entity14991 -infected ticks (or their questing activity) is more likely, when there are freshly emerged adults in the population, i.e. early in the questing season. It was also observed that the temporal distribution of D. reticulatus ticks carrying different @entity14991 genotypes was not random.

title: Uneven seasonal distribution of XXXX and its two 18S rDNA genotypes in questing Dermacentor reticulatus ticks in urban habitats.

entities_list: @entity743 :: ('MESH:D001404', 'Disease') :: ['Babesia canis', 'babesiosis']

answer: @entity743 :: (MESH:D001404,Disease) :: ['Babesia canis']


abstract: Liver resection is essential part of @entity14 (CLM) treatment. Mean 5-year @entity1349 after resection achieves 30-45%. There are many factors influencing long-term outcomes, and among them the inflammatory response to @entity5 plays an important role. THE AIM OF THE STUDY: was evaluation of outcomes and treatment safety of @entity1 with metastatic @entity14 to the liver with estimation of prognostic factors. MATERIAL AND METHODS: 130 consecutive @entity1 (70 @entity1 and 60 @entity1 ) operated in MSC Institute and @entity5 Center in Gliwice from 2001 to 2009 due to colorectal liver metastases were analysed. Age of the @entity1 ranged from 33 to 82 years (median 60 years). 96 (74%) @entity1 underwent potentially radical resection, and in remaining 34 (26%) was performed radiofrequency ablation (RFA) alone or combined with the resection. In the resection group 37 right hepatectomies, 11 left hepatectomies, 28 segmentectomies and 20 metastasectomies were performed. Disease-free survival (DFS) and @entity1349 ( @entity1349 ) were statistically analysed using the Kaplan-Meier method. Factors determining DFS and @entity1349 were analysed using Cox regression model. RESULTS: In the resection group the 3- and 5-years @entity1349 was 64,5% and 46,6% respectively, and the 3- and 5-years DFS was 32% and 30,5% respectively. In the RFA group the 3- and 5-years @entity1349 was 33% and 9,5%. Statistically significant prognostic factors in the resection group in uni- and multivariate analysis were: grade and nodal involvement of the @entity5 , diameter of metastatic focus, positive and narrow (<1 mm) resection margins, preoperative @entity2002 level, preoperative neutrophil to lymphocyte ratio and leukocyte amount of the peripheral blood. The perioperative mortality rate was 3%. CONCLUSIONS: Liver resection due to colorectal liver metastases is a safe and effective method resulting in high survival rates. We confirmed some generally accepted prognostic factors influencing longterm outcomes and shown the impact of inflammatory response. We also confirmed the hypothesis that preoperative plasma @entity2002 level influences outcomes after liver resection due to CLM.

title: Evaluation of outcomes and treatment safety of @entity1 with metastatic XXXX to the liver with estimation of prognostic factors.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer', 'primary tumor']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer liver metastases', 'colorectal cancer']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: OBJECTIVE: To determine whether treatment with recombinant activated factor VII (rFVIIa) will prevent progression of @entity548 in nonsurgical hemorrhagic @entity131 ( @entity131 ). METHODS: Chart review from the @entity130 registry of a level 1 @entity130 center between January 1, 2002 and December 31, 2004 identified 2 @entity1 who received rFVIIa for progressive @entity131 . These @entity1 were given a single dose of rFVIIa (120 mcg/kg) after a repeat head computed tomography (CT) scan showed worsening of @entity510 . Pre-rFVIIa and post-rFVIIa coagulation parameters and postintervention CT scans were performed. A matched convenience sample was drawn from the institution's @entity130 registry reflecting similar injury patterns. RESULTS: The 2 @entity1 who received rFVIIa were ages 61 and 79 years; the @entity1 in the matched convenience sample were 57 and 63 years. Both sets of @entity1 comprised 1 @entity1 and 1 @entity1 who had suffered blunt @entity130 , including @entity131 , and were matched according to age, gender, and injury severity score (ISS). During their hospital course, repeat CT scans documented worsening of @entity932 in both cohorts. In the rFVIIa @entity1 , follow-up CT showed overall improvement of @entity542 compared with the convenience sample. The rFVIIa @entity1 also saw an appreciable decrease in both prothrombin time (PT) and international normalized ratio (INR). CONCLUSIONS: In @entity131 , rFVIIa has the potential to limit or even halt the progression of @entity548 that would otherwise place growing pressure on the brain. A prospective, randomized multicenter trial is planned to elucidate this hypothesis.

title: Effects of recombinant activated factor VII in traumatic nonsurgical XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'man']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'hemorrhagic TBI', 'traumatic brain injury']

entities_list: @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['intracranial bleeding']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury']

answer: @entity932 :: (MESH:D020300,Disease) :: ['intracranial hemorrhage']


abstract: Monitor peptide stimulates cholecystokinin ( @entity6140 ) release from the intestine, but the cellular mechanisms responsible for this effect are uncertain. In the present study, the roles of membrane potential difference and @entity460 influx in monitor peptide-mediated @entity6140 release were examined in a perifusion system containing isolated mucosal cells from the @entity35 duodenum. This method represents an in vitro system in which @entity6140 -releasing cells can be challenged with secretagogues or other maneuvers to study the dynamics of hormone secretion. High concentrations of @entity4338 (50 mM), which reduce electrical potential difference across the cell membrane, caused the release of @entity6140 . This effect was inhibited by the @entity460 channel blocker @entity13718 . Monitor peptide stimulated @entity6140 release in a dose-dependent manner at concentrations from 3 x 10(-12) to 3 x 10(-8) M. The requirement for extracellular @entity460 in secretagogue-stimulated release of @entity6140 was investigated using @entity4526 ( @entity4527 ), a @entity460 chelator, and @entity13718 . A @entity460 -free environment supplemented with 2 mM @entity4527 completely inhibited @entity6140 secretion in response to stimulatory doses of monitor peptide. @entity6140 secretion was restored when @entity460 was reintroduced into the system. Similarly, @entity13718 completely blocked monitor peptide-stimulated @entity6140 release. These data indicate that membrane depolarization and monitor peptide stimulate the release of @entity6140 through @entity460 -dependent mechanisms, suggesting that increases in intracellular @entity460 within @entity6140 cells are likely to be important in @entity6140 release.

title: Role of XXXX in monitor peptide-stimulated cholecystokinin release from perifused intestinal cells.

entities_list: @entity4526 :: ('CHEBI:30740', 'Chemical') :: ["ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid"]

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: Inflammatory processes occur in the central nervous system (CNS) through mechanisms that differ from other @entity32 , and with distinct cellular effects. @entity528 in @entity4008 is not a monocausal event, but is mediated by several factors. One is possible direct @entity137 of bacterial compounds. @entity26799 (LTA) is a cell wall component unique to Gram-positive bacteria. In a previous report, LTA could interact with @entity45685 to induce NF-kappaB activation, which is involved in transcriptional regulation of adhesion molecules, enzymes and cytokines. Although there are many aspects to neuroinflammation, the pathways involving the @entity4665 and subsequent generation of @entity3009 clearly play a role. LTA has been shown to stimulate inflammatory responses in a number of in vivo and in vitro experimental models. However, little was known about the molecular mechanisms of LTA implicated in inflammatory responses in neurons. In this study, we characterized the mechanisms underlying signaling transduction in @entity35 cortical neuronal cells challenged by LTA. Here, we first showed that in @entity35 cortical neuronal cells, LTA might activate protein @entity669 kinase (PTK), @entity2434 -specific phospholipase C (PC-PLC), and @entity4357 -specific phospholipase C (PI-PLC) to induce protein kinase Cepsilon activation, which in turn induces @entity2509 ( @entity2509 ) activation, finally inducing @entity1421 release and @entity4665 synthesis.

title: @entity26799 induces @entity1421 release and cyclooxygenase-2 synthesis in XXXX cortical neuronal cells: involvement of PKCepsilon and @entity2509 activation.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity4008 :: ('MESH:D016920', 'Disease') :: ['bacterial meningitis']

entities_list: @entity4357 :: ('MESH:D010716', 'Chemical') :: ['phosphatidylinositol']

entities_list: @entity2509 :: ('24338(Tax:10116)', 'Gene') :: ['extracellular signal-regulated kinase', 'ERK']

entities_list: @entity2434 :: ('MESH:D010713', 'Chemical') :: ['phosphatidylcholine']

entities_list: @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['Neuronal injury']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity26799 :: ('MESH:C009900', 'Chemical') :: ['Lipoteichoic acid']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The existence of a negative ERG component following the b-wave has been known for a long time. Recently, in unilateral macaque experimental @entity726 , a negative response in flash electroretinograms under scotopic as well as photopic conditions has been shown to be greatly reduced or absent compared to the healthy fellow eye. The aim of this pilot study was to test whether a late negative electroretinogram component is reduced also in @entity1 @entity726 @entity1 under different stimulus conditions. Dark-adapted ganzfeld flash electroretinograms were recorded after 30 min of dark using two test conditions, obtained as optimal in pilot studies on controls. Under the scotopic condition I white Xenon-flashes of intensity 0.53 Log photopic Td s were presented on a low white background of 1.38 Log scotopic Td. Under the more photopic condition II orange flashes of intensity -0.37 Log photopic Td s were presented on a blue-adapting background of 2.5 Log scotopic Td. Nine controls and 18 @entity1 with advanced @entity726 were analyzed. The amplitude of the negative response was not significantly reduced in @entity726 @entity1 (condition I: -28.5+/-23.7 microV; condition II: -25.2+/-19.7 microV) compared to controls (condition I: -41.4+/-36.6 microV; condition II: -31.3+/-26.2 microV). The peak latency of the responses under condition I and II did not differ significantly between @entity1 and controls. Thus, the late negative electroretinogram component in ganzfeld flash electroretinograms obtained under scotopic and more photopic conditions does not seem to distinguish as easy between @entity1 controls and @entity726 @entity1 as animal experiments suggest.

title: The negative response of the flash electroretinogram in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

answer: @entity726 :: (MESH:D005901,Disease) :: ['glaucoma']


abstract: BACKGROUND: Metastatic @entity356 confers a dismal prognosis. Several prognostic factors are needed to distinguish @entity1 that will benefit from chemotherapy. In this setting, the prognostic impact of DNA ploidy is still unclear. MATERIALS AND METHODS: The records of 61 @entity1 with metastatic @entity356 were retrospectively reviewed. Response to chemotherapy and @entity1349 ( @entity1349 ) were assessed and correlated to @entity5 DNA ploidy index, which was calculated by cytometric image analysis. RESULTS: The median value of DNA ploidy index was 2.3. @entity1 with a low index responded better to chemotherapy than those with a higher index (p<0.01). Nevertheless, when the median value was used as a cut-off, no significant correlation of DNA ploidy index with response to chemotherapy (p=0.41) or @entity1349 (p=0.09) was observed. CONCLUSION: The prognostic role of DNA ploidy in metastatic @entity356 is still debatable. In this study, a low DNA ploidy index was associated with favorable prognosis; however, a suitable cut-off value is not yet available.

title: DNA ploidy: a prognostic factor of response to chemotherapy and survival in metastatic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric adenocarcinoma']


abstract: OBJECTIVE: To study the diagnosis and treatment of @entity1358 . METHOD: From January 1993 to December 2000 the data of 271 cases of @entity1358 were reviewed. RESULTS: Ultrasonography and CT scanning were still the main diagnostic methods. Surgical operation was performed on 234 @entity1 . Radical nephrectomy was performed on 197 @entity1 (72.6%); Nephron sparing surgery was performed on 19 @entity1 ; @entity3 resection was performed on 6 @entity1 and other procedures for 12. The pathological results showed that 137 cases (61.4%) were @entity1358 , 18 cases (8. 1%) of @entity420 , 32 cases (14. 3%) being combination of the above two varieties, 23 cases (10.3%) of renal @entity4937 , 13 cases being renal cell of other types. And 210 cases (77.5%) had been successfully followed up. The 1, 3, 5 and 10 year survival rates were 95.3% (182/191), 88.7% (107/122), 74.7% (56/75) and 32.1% (10/31) respectively. CONCLUSIONS: Ultrasonography is the first select examination method of detecting of @entity1358 , and CT scanning is the most valuable diagnostic mean. Early diagnosis and prompt radical nephrectomy or nephron sparing nephrectomy are the critical points for achieving long-term survivals of @entity1 with @entity1358 .

title: [Clinical analysis of XXXX : report of 271 cases].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4937 :: ('MESH:D000231', 'Disease') :: ['papillary adenocarcinoma']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'clear cell carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastatic tumor']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['granular cell carcinoma']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['renal cell carcinoma']


abstract: @entity14 puts a major burden on the hospital resources because of its frequency and demands for extensive surgery. Screening with @entity66 at an earlier stage in a number of @entity1 . The possible influence upon length of hospital stay is investigated in a randomised trial of 61,938 @entity1 between 45 and 74 years, 30,970 being invited to screening with Hemoccult-II bianually. The first screening was accomplished in 20,672 @entity1 and 17,284 have completed three screenings from 1985 to 1990. The test was positive in 1%, and further examination (colonoscopy) among these revealed @entity5 in 74 and @entity652 in 248 @entity1 . The whole screening group contained 239 @entity1 with @entity5 and 380 with @entity652 , the figures among controls being 216 and 181, respectively. The excess hospital stay in the screening group was 487 days (7%), the major part being one-day admissions for colonoscopy. The average stay was shorter in the screening group and shortest among those with @entity14 being detected because of positive Hemoccult-II. Measurements of hospital stay included admissions for diagnosis, treatment and complications as well as recurrence within the first year of diagnosis. In conclusion, the excess use of hospital days introduced by screening was limited in the first five years. This will probably later disappear and become negative because of decreasing numbers of @entity5 in the screening group. @entity5 and admissions for possible @entity14 will also be less frequent in the screening group.

title: [Requirement of hospital beds in connection with screening for XXXX . The first 5-years of a randomized population survey].

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Hemoccult-II detects the disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Advanced cancers', 'cancers', 'cancer']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'colorectal cancer', 'colorectal neoplasia']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: @entity5 results from an undesirable imbalance between cellular proliferation and apoptosis. Both processes may be modulated at the level of gene expression, viz., @entity876 and c-Ha-ras, by dietary bioactive components such as @entity4025 . We tested the time-dependent effect of @entity4025 on gene and protein expression in @entity19 cells containing a mutated @entity1 c-Ha-ras oncogene. We demonstrate cyclic @entity4025 -mediated expression of @entity876 , @entity7465 , @entity994 (cip/waf), Rb, and @entity11486 at both the RNA and the protein level at <8 h. However, ras was not differentially expressed at either the RNA or the protein level. @entity876 was upregulated followed by p21cip/waf, then @entity7465 , and @entity11486 , all downstream @entity876 -activated targets. RNA transcription increased at >8 h for all genes except @entity876 , but protein levels did not suggest uncoupling of transcription and translation. At 24 h, both @entity876 and Rb expression returned to baseline, suggesting collapse of DNA structure and spindle assembly checkpoints characteristic of mitotic catastrophe. In summary, @entity4025 at <8 h induced @entity876 -mediated effects, including apoptosis and cell-cycle arrest (G2/M). However, later, it induced cell-cycle checkpoint dysfunction, indicative of mitotic catastrophe. Thus, future studies should better elucidate the temporal mechanism of the dietary bioactive agent @entity4025 on @entity5 cells.

title: Time-dependent @entity4025 -mediated mRNA and protein expression associated with cell cycle in @entity19 cells containing mutated XXXX c-Ha-Ras.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer']

entities_list: @entity4025 :: ('MESH:C059514', 'Chemical') :: ['resveratrol']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: AIMS: Hepatic resection can cure @entity157 ( @entity157 ). However, the optimal extent of resection remains controversial. Major hepatectomy could minimize a @entity5 recurrence, but it is harmful due to decreased hepatic functional reserve. @entity419 positron emission tomography (FDG-PET) scans are known as their reflection @entity5 differentiation and biological activity in @entity157 . To evaluate a benefit of major hepatectomy for @entity157 , we performed this retrospective analysis in @entity1 with well-preserved hepatic function, and further analyzed in the subset identified by preoperative FDG-PET. METHODS: We reviewed the medical records of 189 @entity1 with @entity157 who underwent curative resection between August 2004 and December 2010 at two institutes. All @entity1 underwent anatomical resection, either by major or minor hepatectomy. RESULTS: Median overall survival did not differ significantly between the major and minor hepatectomy groups (29.4 versus 26.3 months, p = 0.269). However, the major hepatectomy group had a better recurrence-free survival (24.5 versus 19.9 months, p = 0.004). On multivariate analysis, the presence of intrahepatic @entity3 independently predicted overall survival (p = 0.009), but other examined variables did not. Overall survival and recurrence-free survival were significantly better following major hepatectomy rather than minor hepatectomy in @entity1 whose preoperative FDG-PET indicated that the maximum @entity5 ( @entity5 ) was >= 4 and the @entity5 -to-nontumor SUV ratio (TNR) was >= 1.5. CONCLUSIONS: Our findings suggest that preoperative FDG-PET may be useful in identifying @entity1 with favorable hepatic reserve who are most likely to benefit from major rather than minor hepatectomy.

title: A survival benefit of major hepatectomy for @entity157 identified by preoperative @entity419 positron emission tomography in XXXX with well-preserved hepatic function.

entities_list: @entity419 :: ('MESH:D019788', 'Chemical') :: ['[18F] fluorodeoxyglucose']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'SUVtumor', 'standardized uptake value of the tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND AND PURPOSE: The purpose of this study was to assess the incidence of late rebleeding of ruptured @entity438 treated with detachable coils. @entity1 AND METHODS: A clinical follow-up study was conducted in 393 consecutive @entity1 with a @entity1756 treated with detachable coils between January 1995 and January 2003. Late rebleeding was defined as recurrent @entity548 from a coiled @entity439 >1 month after coiling. One @entity1 was lost to follow-up. Total clinical follow-up of the 392 @entity1 who were coiled for @entity1756 was 18,708 months (1559 @entity1 years; median, 48 months; mean, 47.7 months; range, 0-120 months). RESULTS: Four @entity1 suffered late rebleeding from the coiled @entity439 at 8, 12, 30, and 40 months after coiling, respectively. Two of these @entity1 died. Another @entity1 died of probable rebleeding 4 months after coiling. The incidence of late rebleeding was 1.27% (5/393) and mortality of late rebleeding was 0.76% (3/393). The annual late rebleeding rate was 0.32%, and the annual mortality rate from late rebleeding was 0.19%. During the follow-up period, 53 coiled @entity439 in 53 @entity1 (13%) were additionally treated: 35 @entity439 (8.9%) were additionally treated with coils, 16 @entity439 (4.1%) were additionally clipped, and 2 @entity439 (0.5%) were additionally treated with parent @entity432 . CONCLUSION: The late rebleeding rate after coiling of @entity1756 is very low. Follow-up of @entity1 with a coiled @entity439 is mandatory to identify @entity439 that need additional treatment after reopening.

title: Late rebleeding of ruptured XXXX treated with detachable coils.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['intracranial aneurysms']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysm']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['vessel balloon occlusion']

entities_list: @entity1756 :: ('MESH:D017542', 'Disease') :: ['ruptured cerebral aneurysms', 'ruptured aneurysm']

answer: @entity438 :: (MESH:D002532,Disease) :: ['intracranial aneurysms']


abstract: BACKGROUND: Because of several side effects, the corticosteroid usage has been minimized in kidney transplantation. The increased acute rejection episodes associated with their withdrawal may counterbalance with induction treatment using polyclonal antilymphocyte globulin (ALG). The effects of ALG on blood cell phenotype have already been the subject of several reports. However, to date, no data are available concerning the comparison of blood phenotype when ALG is given with or without @entity230 and no gene profiling study has been performed. METHODS: We report here on a longitudinal blood cell analysis of a selected cohort of kidney recipients enrolled in a randomized study of @entity134 avoidance or withdrawal (during 6 months) during ALG induction. RESULTS: In the two groups, ALG quickly and massively depleted all the T cells and natural killer cells, but not B cells. Interestingly, the @entity2905 -driven homeostatic proliferation of @entity404 and CD8T cells strongly differed with persistent low @entity404 (including @entity404 ) T-cell counts. Effector memory CD8T cells reappeared rapidly. ALG induced apoptosis-associated molecules and increased myeloid cell genes. However, few genes were found differentially expressed with a low fold ratio between the two groups during and at distance of corticotherapy. CONCLUSION: Thus initial @entity134 avoidance or withdrawal associated with ALG induction has a weak influence on phenotype and transcriptional pattern of blood leukocytes. In contrast, ALG therapy induces an early and strong depletion of all T-cell subsets with contrasted long-lasting homeostatic regulation.

title: Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without XXXX .

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity2905 :: ('MESH:D008231', 'Disease') :: ['lymphopenia']

answer: @entity230 :: (MESH:D013256,Chemical) :: ['steroids']


abstract: BACKGROUND/AIM: The aim of the present study is to compare the postoperative and long-term outcomes of @entity6220 ( @entity6220 ) and @entity4559 ( @entity4559 ). METHODS: Clinical, pathological and long-term data were compared between 22 @entity1 who underwent @entity6220 and 25 @entity1 who underwent @entity4559 (2002-2012). RESULTS: The median length of resected pancreas was 8.5 cm in the @entity4559 group and 5 cm in the @entity6220 group (p < 0.001). The median estimated @entity190 was significantly lower in the @entity6220 group (p = 0.019). Morbidity was 50% for CPs and 40% for SPDPs (p = 0.564). The rate of pancreatic fistulae was 36% for CPs and 40% for SPDPs (p = 0.530). The rate of new-onset @entity6 was nil in the successful @entity6220 group and 16% in the @entity4559 group (p = 0.111). CONCLUSION: Morbidity and pancreatic @entity292 rates are not higher after @entity6220 when compared to @entity4559 . The loss of normal pancreatic tissue is significantly lower for @entity6220 , and thus there is potentially better preservation of the pancreatic endocrine functions. @entity6220 should be considered only in selected cases when preservation of the pancreas is of utmost importance, especially for lesions situated at the level of the pancreatic neck.

title: Central pancreatectomy versus XXXX : a comparative analysis of early and late postoperative outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4559 :: ('MESH:D013160', 'Disease') :: ['spleen-preserving distal pancreatectomy', 'SPDP']

entities_list: @entity6220 :: ('MESH:D020279', 'Disease') :: ['CP', 'central pancreatectomy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

answer: @entity4559 :: (MESH:D013160,Disease) :: ['spleen-preserving distal pancreatectomy']


abstract: OBJECTIVES: To assess the comorbidity of @entity245 /delay in @entity1 with selective mutism (SM) and to assess other comorbid symptoms such as @entity148 , @entity11795 , and @entity2464 . METHOD: Subjects with SM and their matched controls were evaluated by a comprehensive assessment of the @entity1 and by means of a parental structured diagnostic interview with focus on developmental history. Diagnoses were made according to DSM-IV. RESULTS: A total of 54 @entity1 with SM and 108 control @entity1 were evaluated. Of the @entity1 with SM, 68.5% met the criteria for a diagnosis reflecting @entity245 /delay compared with 13.0% in the control group. The criteria for any @entity148 diagnosis were met by 74.1% in the SM group and for an @entity29082 by 31.5% versus 7.4% and 9.3%, respectively, in the control group. In the SM group, 46.3% of the @entity1 met the criteria for both an @entity148 diagnosis and a diagnosis reflecting @entity245 /delay versus 0.9% in the controls. CONCLUSIONS: SM is associated with @entity245 /delay nearly as frequently as with @entity148 . The mutism may conceal developmental problems in @entity1 with SM. @entity1 with SM often meet diagnostic criteria for both a developmental and an @entity148 .

title: Selective mutism and comorbidity with @entity245 /delay, XXXX , and @entity29082 .

entities_list: @entity1 :: ('9606', 'Species') :: ['child', 'children', 'Children']

entities_list: @entity2464 :: ('MESH:D004688', 'Disease') :: ['encopresis']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['developmental disorder']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety disorder', 'anxiety', 'anxiety disorders']

entities_list: @entity29082 :: ('MESH:D019960', 'Disease') :: ['elimination disorder']

answer: @entity148 :: (MESH:D001008,Disease) :: ['anxiety disorder']


abstract: It seems to evident that deformation of the hand as a result of @entity2074 should cause weakness and overall functional impairment of the hand, and an increase of range of motion of the fingers as a result of the operation should effect in improvement of these parameters. The objective of this study was to investigate the effect of extension loss of fingers, number of fingers involved and age of the @entity1 on the power and dexterity of the hand, as well as influence of the age of the @entity1 and recovery of extension of the fingers on the power and dexterity of the hand after surgery for @entity2074 . 54 @entity1 in an age range 32-83 years (mean 60) with the disease lasting av. 5 years underwent @entity512 . Total extension loss of the fingers and total grip strength were measured and dexterity of the hand was assessed with DASH questionnaire prior to surgery. @entity1 were followed-up for 1 year and assessments were repeated at 1, 3 and finally at 12 months. Median values of measured variables at presentation were as follows: extension loss 80 degrees, total grip strength 41 kG, and DASH score 54. At 12 months median extension loss decreased to 10 degrees (stat. sign.), DASH score to 32 (stat. sign. improvement of dexterity) and grip strength decreased slightly to 40 kG. An analysis of the relationship between the variables showed that severity of the contracture (expressed as an extension loss) had no effect on dexterity of the hand but had significant influence on deterioration of the total grip strength. Number of fingers involved did affect neither dexterity nor power of the hand. Age of the @entity1 did not influence subjective feeling of dexterity of the hand, however, older @entity1 experienced lesser functional benefit from the operation, than younger @entity1 . An increase of extension of the fingers following surgery had significant beneficial effect on subjective improvement of the dexterity of the hand, but had not effect on the increase of power of the hand.

title: [An assessment of the influence of the severity of XXXX on the dexterity of the hand before and after surgery].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity512 :: ('MESH:C567308', 'Disease') :: ['subtotal fasciectomy']

entities_list: @entity2074 :: ('MESH:D004387', 'Disease') :: ["Dupuytren's contracture"]

answer: @entity2074 :: (MESH:D004387,Disease) :: ['Dupuytren's contracture']


abstract: UNASSIGNED: Purpose To compare the clinical, imaging, and histopathologic features of @entity0 detected at screening magnetic resonance (MR) imaging, screening mammography, and those detected between screening examinations ( @entity5 ) in @entity1 at high risk. Materials and Methods This retrospective institutional review board-approved, HIPAA-compliant review of 7519 @entity1 at high risk for @entity0 who underwent screening with MR imaging and mammography between January 2005 and December 2010 was performed to determine the number of screening-detected and @entity5 diagnosed. The need for informed consent was waived. Medical records were reviewed for age, risk factors (family or personal history of @entity0 , @entity5345 mutation status, history of high-risk lesion or mantle radiation), @entity5 histopathologic results, and time between diagnosis of interval @entity5 and most recent screening examination. The   (2) test and logistic regression methods were used to compare the features of screening MR imaging, screening mammography, and @entity5 . The Wilcoxon signed-rank test was used to calculate P values. Results A total of 18 064 screening MR imaging examinations and 26 866 screening mammographic examinations were performed. Two hundred twenty-two @entity5 were diagnosed in 219 @entity1 , 167 (75%) at MR imaging, 43 (19%) at mammography, and 12 (5%) @entity5 . Median age at diagnosis was 52 years. No risk factors were associated with screening MR imaging, screening mammography, or interval @entity5 (P > .06). @entity5 found at screening MR imaging were more likely to be @entity3 (118 of 167 [71%]; P < .0001). Of the 43 @entity5 found at screening mammography, 38 (88%) manifested as calcifications and 28 (65%) were @entity513 in situ. Interval @entity5 were associated with nodal involvement (P = .005) and the triple-negative subtype (P = .03). Conclusion In @entity1 at high risk for @entity0 who underwent screening with mammography and MR imaging, invasive @entity5 were more likely to be detected at MR imaging, whereas most @entity5 detected at screening mammography were @entity513 in situ. Interval @entity5 were found infrequently and were more likely to be node positive and of the triple-negative subtype. (  ) RSNA, 2016.

title: @entity0 Detected at Screening MR Imaging and Mammography in XXXX at High Risk: Method of Detection Reflects Tumor Histopathologic Results.

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers', 'breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancers', 'interval cancers', 'cancers', 'cancer']

entities_list: @entity513 :: ('MESH:D044584', 'Disease') :: ['ductal carcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive cancer']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: The aim of this study was to address the intriguing issue of the role of the @entity442 system in longevity looking at the role of different components of IGF system. Vital status was ascertained in 1,197 @entity1 and @entity1 aged greater than or equal to 65 years from the InCHIANTI study. Hormonal levels were categorized into quartiles, and ratio of @entity442 to @entity10116 was calculated. The relationship between hormones and mortality was tested by Cox proportional hazard models adjusted for age, sex, and confounders. During the 8-year follow-up period, 240 died and 957 survived. Lowest quartiles of @entity442 and @entity10116 were considered as reference. Compared with the lowest quartiles, @entity442 in upper quartiles was a negative predictor of mortality independent of age and sex (p = .01) but not independent of @entity10116 and other confounders. @entity10116 in second-third quartiles was negatively associated and that in the fourth quartiles was positively associated with risk of @entity204 . @entity442 / @entity10116 ratio in the lowest quartiles was a strong positive predictor of mortality, in age- and sex-adjusted model (p = .005), and independent of additional confounders (p = .037). High @entity10116 and low @entity442 / @entity10116 ratio are associated with all-cause mortality in older population.

title: @entity442 bioactivity plays a prosurvival role in older XXXX .

entities_list: @entity442 :: ('3479', 'Gene') :: ['insulin-like growth factor (IGF)-1', 'IGF-1']

entities_list: @entity10116 :: ('3484', 'Gene') :: ['IGF-binding protein (IGFBP)-1', 'IGFBP-1']

answer: @entity1 :: (9606,Species) :: ['participants']


abstract: We have reported the results of a previous Phase II trial of two courses of neoadjuvant @entity1138 (6 mg/m2), @entity1260 (3 g/m2) and @entity900 (50 mg/m2) (MIC) in squamous or anaplastic @entity189 . In this current study, we have investigated whether there was any clinical benefit in extending the preoperative treatment to four courses for @entity1 who responded after two courses. Response was assessed by barium swallow, which was compared with previous barium swallows performed prior to any treatment and after the second course of MIC. Of an initial 43 @entity1 , 27 (63%) were assessed as responders after two courses of MIC. Twenty of these 27 @entity1 were entered into the study with a view to receiving two further courses of MIC prior to surgery. Seventeen completed four courses. Five @entity1 were complete responders after two courses and remained complete responders after four courses. Twelve @entity1 were partial responders after two courses; six of these became complete responders after four courses, five remained partial responders, and one showed progression. @entity137 and @entity1665 were increased after extending the number of courses beyond two. On pathological assessment, three @entity1 with a complete response after four courses, and one with a complete response after three courses, had microscopic clearance of @entity5 . Extension beyond two courses of neoadjuvant MIC gives an improvement in response, as judged by barium assessment, but increases @entity137 , cost of treatment and delay before surgery. Although the numbers are small, the results suggest that a worthwhile improvement in the radiological response of squamous or anaplastic @entity5 may be gained by proceeding beyond two courses of @entity1531 randomized trial, with larger numbers of @entity1 , is needed to show whether there is any improvement in radiological and pathological response rates and in survival to be gained by the extension of treatment beyond two courses.

title: A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Haematological toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'oesophageal tumours']

entities_list: @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma of the oesophagus']

entities_list: @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide']

answer: @entity189 :: (MESH:D002277,Disease) :: ['carcinoma of the oesophagus']


abstract: CONTEXT: The goal of GH replacement with recombinant @entity1 GH (rhGH) is to ameliorate symptoms, signs, and complications of @entity2338 ( @entity2338 ) in the long term. To determine whether the observed short-term beneficial effects of rhGH treatment are sustained in the long term, we evaluated biochemical and anthropometric parameters after 7 years of rhGH replacement. @entity1 AND METHODS: After 2, 5, and 7 years of rhGH replacement, 63 adult @entity2338 @entity1 (30 @entity1 , 52 adult-onset @entity2338 ) were assessed. @entity442 increased during rhGH replacement, and a stable dose of rhGH was reached within 1 year of rhGH substitution. Thereafter, this individualized dose was continued. RESULTS: Plasma levels of total @entity165 and low-density lipoprotein @entity165 decreased even after 5 years of rhGH replacement (11% decrease, P < 0.001; 22% decrease, P < 0.001 respectively). High-density lipoprotein @entity165 levels increased during 7 years of rhGH replacement (1.4 +/- 0.5 mmol/l at baseline vs 1.7 +/- 0.5 mmol/l after 7 years, P < 0.001), whereas @entity412 concentrations remained unchanged. Fasting @entity413 levels increased during follow-up, mainly during the first 2 years of rhGH replacement (4.4 +/- 0.7 mmol/l to 5.0 +/- 1.0 mmol/l, P < 0.001). Body mass index increased during follow-up, whereas waist circumference and waist-to-hip ratio remained unchanged. Diastolic blood pressure decreased (P = 0.002), but when patients using antihypertensive medication were excluded this decrease did not reach significance (P = 0.064). Systolic blood pressure remained unchanged. CONCLUSION: The beneficial effects of rhGH replacement, described after short-term rhGH replacement, are sustained in the long term up to 7 years.

title: Sustained effects of recombinant GH replacement after 7 years of treatment in adults with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'PATIENTS', 'men']

entities_list: @entity2338 :: ('MESH:D004393', 'Disease') :: ['adult GH deficiency', 'GHD']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity2338 :: (MESH:D004393,Disease) :: ['GH deficiency']


abstract: PURPOSE: Adjuvant chemotherapy trial of TS-1 for @entity356 study demonstrated that postoperative @entity11730 chemotherapy for 1  year improved overall survival of locally advanced @entity356 (LAGC) @entity1 . The goals of this study were to evaluate the feasibility and efficacy of neoadjuvant @entity1205 , @entity901 , and @entity11730 (DOS) chemotherapy followed by surgery and adjuvant @entity11730 chemotherapy. METHODS: In this single-center, open-label, phase II study, @entity1 with potentially resectable @entity420 or gastroesophageal junction were eligible. For neoadjuvant chemotherapy, @entity1205 50  mg/m(2) on day (D) 1, @entity901 100  mg/m(2) on D1, and @entity11730 40  mg/m(2) bid orally on D1-14 were administrated every 3  weeks for three cycles. After DOS chemotherapy, gastrectomy was performed, and then, adjuvant @entity11730 40  mg/m(2) bid was given on D1-28 every 6  weeks for 1  year. The primary endpoints were the proportion of @entity1 who did not experience grade 3 or 4 @entity137 (except grade 3 @entity1398 ) and R0 resection rates. RESULTS: A total of 41 @entity1 were enrolled. All @entity1 completed three planned cycles of neoadjuvant chemotherapy without disease progression. Eighteen @entity1 (43.9  %) did not experience any grade 3-4 @entity137 (except grade 3 @entity1398 ) during the neoadjuvant chemotherapy. All @entity1 underwent surgery, and R0 resection was achieved in 40 @entity1 (97.6  %). CONCLUSION: Neoadjuvant DOS chemotherapy could be performed safely with a high R0 resection rate in LAGC @entity1 . A phase III trial is currently underway.

title: A phase II study of neoadjuvant @entity1205 , @entity901 , and @entity11730 (DOS) chemotherapy followed by surgery and adjuvant @entity11730 chemotherapy in potentially resectable gastric or gastroesophageal junction XXXX .

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the stomach']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

answer: @entity420 :: (MESH:D000230,Disease) :: ['adenocarcinoma']


abstract: We have recently isolated and characterized a human monoclonal autoantibody, @entity6253 -h1 (multiple organ-reactive @entity1 1), that reacts with antigens in multiple organs and have shown that this antibody binds to @entity1 growth hormone and a 35,000-mol wt protein. In the present study we generated three monoclonal anti-idiotypic antibodies (4E6, 3E5, and 3F6) against @entity6253 -h1. These anti-idiotypic antibodies specifically reacted with @entity6253 -h1 and not with 26 other multiple organ-reactive monoclonal IgM autoantibodies nor with pooled @entity1 IgM ( @entity1582 proteins). The binding of the anti-idiotypic antibodies to @entity6253 -h1 was inhibited by both @entity1 growth hormone and the 35,000-mol wt protein, which strongly suggests that these antibodies react with epitopes at or near the paratope on @entity6253 -h1. The results of competitive binding experiments revealed that the epitope recognized by 4E6 is distinct from that recognized by 3E5 and 3F6. Using these anti-idiotypic antibodies, lymphocytes and sera from normal individuals were tested for the presence of the 4E6 and 3E5/3F6 idiotopes. By indirect immunofluorescence, the 4E6 idiotope was detected on an average of 1.1% of normal circulating B lymphocytes, and by enzyme-linked immunosorbent assays, the 4E6 and to a lesser extent the 3E5/3F6 idiotopes were found on IgG molecules in sera of normal individuals. In spite of the expression of idiotopes known to be present on @entity6253 -h1, no @entity6253 -h1-like antibody activity was detected in normal sera. Examination of sera from @entity1 with several @entity792 failed to show an increased expression of the 4E6 idiotope as compared with normal controls. These data suggest that anti-idiotypic antibody 4E6 recognizes a public idiotope, the expression of which is not restricted to @entity792 .

title: Anti-idiotypic antibodies against a XXXX multiple organ-reactive autoantibody. Detection of idiotopes in normal individuals and @entity1 with @entity792 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease', 'autoimmune diseases']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: @entity22165 ( @entity22165 ) is a @entity395 with @entity1712 and an increased number of blood or marrow blast (<20%) or an evidence of eosinophil clonality.We evaluated the clinical outcome of 10 @entity1 with @entity22165 . Seven males and three females at a median age of 62 years (range, 23   73) were included. The median leukocyte count at diagnosis was 33.4 3109/l (range, 9.3   175.0) with a median eosinophil count of 15.6 3 109/l (range, 1.5   136.0). Median hemoglobin and platelets were 11.0 g/dl (range, 8.3   13.3) and 158 3 109/l (range, 31.0   891.0), respectively. Clinical manifestations included @entity381 (n 5 7), @entity382 (n 56), @entity712 (n 5 2), and lung infiltrations (n 5 1). Median survival from diagnosis to @entity204 for entire cohort was 22.2 months (range,2.2   186.2). Five of the 10 studied @entity1 developed acute transformation( @entity1129 ) after median of 20 months from diagnosis (range, 1.6   41.9).None of @entity1 with @entity1129 is alive at the time of last follow-up. Median time from @entity1129 to @entity204 was 2 months (range, 1.0   6.1). Among five @entity1 who did not develop @entity1129 , three died in active disease. Two @entity1 are alive in complete remission; first underwent allogeneic stem-cell transplantation preceding by intensive induction chemotherapy;the second remains on @entity2213 with @entity1862 . Except the latter @entity1 , @entity2213 was ineffective in our study population. @entity22165 is a rare and @entity146 with high rate of @entity1129 and resistance to conventional treatment.

title: XXXX has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['hypereosinophilia']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive disease']

entities_list: @entity1862 :: ('MESH:D006918', 'Chemical') :: ['hydroxyurea']

entities_list: @entity22165 :: ('MESH:C580364', 'Disease') :: ['Chronic eosinophilic leukemia-not otherwise specified', 'CEL-NOS']

entities_list: @entity381 :: ('MESH:D013163', 'Disease') :: ['splenomegaly']

entities_list: @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly']

entities_list: @entity395 :: ('MESH:D035583', 'Disease') :: ['rare disorder']

entities_list: @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib']

answer: @entity22165 :: (MESH:C580364,Disease) :: ['Chronic eosinophilic leukemia-not otherwise specified']


abstract: BACKGROUND: Inflammatory markers have been associated with @entity385 risk and prognosis after @entity299 . Their relationship to prognosis after @entity64 is unsettled. METHODS: A population-based study of @entity64 risk factors in 467 @entity1 with first @entity385 was undertaken to determine whether levels of high-sensitivity C-reactive protein ( @entity6511 ( @entity6511 ) predict risk of @entity64 recurrence, other vascular events, and @entity204 . RESULTS: Levels of @entity6511 and hs-CRP were weakly correlated (r = 0.09; P = .045). High-sensitivity CRP, but not @entity6511 , was associated with @entity64 severity. After adjusting for age, sex, race and ethnicity, history of @entity453 , @entity6 , @entity101 , @entity407 , @entity955 , smoking, and hs-CRP level, compared with the lowest quartile of @entity6511 , those in the highest quartile had an increased risk of recurrent @entity64 (adjusted hazard ratio, 2.08; 95% confidence interval, 1.04-4.18) and of the combined outcome of recurrent @entity64 , MI, or vascular @entity204 (adjusted hazard ratio, 1.86; 95% confidence interval, 1.01-3.42). After adjusting for confounders, hs-CRP was not associated with risk of recurrent @entity64 or recurrent @entity64 , @entity583 , or vascular @entity204 but was associated with risk of @entity204 (adjusted hazard ratio, 2.11; 95% confidence interval, 1.18-3.75). CONCLUSIONS: Inflammatory markers are associated with prognosis after first @entity385 and may offer complementary information. @entity6511 may be a stronger predictor of recurrent @entity64 risk. Levels of hs-CRP, an acute-phase reactant, increase with @entity64 severity and may be associated with mortality to a greater degree than recurrence.

title: High-sensitivity C-reactive protein, XXXX , and outcome after @entity385 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity6511 :: ('7941', 'Gene') :: ['Lipoprotein-associated phospholipase A(2)', 'Lp-PLA2', 'hs-CRP) and lipoprotein-associated phospholipase A(2)']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity6511 :: (7941,Gene) :: ['lipoprotein-associated phospholipase A2']


abstract: Objective of this study was the characterization of @entity131 induced by a "Controlled Cortical Impact" with magnetic resonance imaging techniques. The impact was applied to the intact dura of the left hemisphere in @entity35 . The pneumatic impactor was accelerated to a velocity of 7 m/s contusing the left temporo-parietal hemisphere to a depth of 2 mm. Posttraumatic hemispheric swelling and water content were determined gravimetrically, Evans Blue extravasation photometrically, and volume of @entity63 by TTC-staining and planimetry. Magnetic resonance imaging was performed by a Bruker biospec 24/40, 90 min, 24 and 72 h post @entity130 using a T2w RARE sequence, a T1w sequence, before and after application of contrast agent, and a set of diffusion weighted images for calculation of ADC-maps. Data analysis was performed using a cluster algorithm enabling to interpret corresponding image pairs simultaneously. T2w imaging indicates the maximum @entity4 about 24 h post @entity130 . Blood-brain barrier damage, detected by T1w imaging, is more predominant in the early posttraumatic phase. The cluster algorithm detects different @entity4 components: from the necrotic core to the perifocal vasogenic rim. MRI in combination with the cluster algorithm will hopefully be a valuable tool in testing neuroprotective agents.

title: Magnetic resonance imaging studies with cluster algorithm for characterization of brain edema after controlled cortical XXXX (CCII).

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['traumatic brain injury']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats']

answer: @entity130 :: (MESH:D014947,Disease) :: ['impact injury']


abstract: @entity2805 is devastating for the @entity1 , however the pathophysiology and treatment remain unknown after decades of research. The process follows deep @entity130 , occurs only on certain body parts, does not occur in the early fetus or in animals, and is a localized event. This suggests that an anatomic structure in @entity1 , deep dermis may be involved. The dermis is a matrix perforated by cones containing many structures including skin appendages and fat domes. We hypothesized that studying the cones might reveal a structure related to @entity2318 . We examined tangential wounds from various body parts on @entity1 cadavers along with skin histology from various @entity1 body parts, the early fetus, @entity121 , @entity2805 , and two other species- @entity35 and @entity95 . We found that the cones may in fact be the structure. They exist where @entity2805 -cheek, neck, chest, abdomen, back, buttock, arm, forearm, dorsal hand, thigh, leg, dorsal foot, helix and ear lobe. They do not exist where @entity2805 does not occur-scalp, forehead, concha, eyelid, palm, early fetus, and in @entity35 , or @entity95 . It also became apparent that the cones have been omitted from most considerations of skin histology. We suggest that the cones need to be studied in relation to @entity1184 @entity2318 and restored to skin diagrams.

title: Cones of skin occur where XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit']

entities_list: @entity2805 :: ('MESH:D017439', 'Disease') :: ['hypertrophic scar occurs', 'Hypertrophic scarring', 'hypertrophic scars', 'hypertrophic scar']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['partial thickness burns']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['dermal injury']

answer: @entity2805 :: (MESH:D017439,Disease) :: ['hypertrophic scar occurs']


abstract: The aim of this study was to explore the mechanisms of resistance against invading @entity10130 larvae in @entity1707 . @entity1707 received a low dose of 100 A. suum eggs daily for 14 weeks. This resulted in a >99% reduction in the number of larvae that could migrate through the host after a challenge infection of 5000 A. suum eggs, compared to na  ve @entity1707 . Histological analysis at the site of parasite entry, i.e. the caecum, identified @entity1712 , @entity5310 and @entity1373 . Increased local transcription levels of genes for @entity50196 , @entity50197 , @entity50198 and eotaxin further supported the observed eosinophil influx. Further analysis showed that eosinophils degranulated in vitro in response to contact with infective Ascaris larvae in the presence of serum from both immune and na  ve animals. This effect was diminished with heat-inactivated serum, indicating a complement dependent mechanism. Furthermore, eosinophils were efficient in killing the larvae in vitro when incubated together with serum from immune animals, suggesting that A. suum specific antibodies are required for efficient elimination of the larvae. Together, these results indicate an important role for eosinophils in the intestinal defense against invading A. suum larvae.

title: A role for eosinophils in the intestinal immunity against infective XXXX larvae.

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia']

entities_list: @entity5310 :: ('MESH:D008415', 'Disease') :: ['mastocytosis']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['goblet cell hyperplasia']

entities_list: @entity50198 :: ('100514365', 'Gene') :: ['eosinophil peroxidase']

answer: @entity10130 :: (6253,Species) :: ['Ascaris suum']


abstract: The most common side effect of opioid therapy is @entity1142 . It is often difficult to treat and is believed to be primarily a peripheral effect. Single large doses of oral @entity1510 have been shown to be efficacious in reversing opioid-induced @entity1142 . However, they often cause the unwanted side effect of @entity1337 reversal. This study evaluated the effects on @entity1142 and @entity1337 of low doses of oral @entity1510 given three times daily. @entity1 taking stable doses of opioids with complaints of @entity1142 were recruited for this double-blind, randomized, placebo-controlled study. @entity1 were given 4 mg or 2 mg of oral @entity1510 , or placebo, three times daily. Stool frequency and symptoms related to @entity1142 were recorded daily. @entity1 also recorded the daily amount of analgesics required to maintain @entity158 control. Nine @entity1 were recruited for the study. All the @entity1 who received oral @entity1510 had some improvement in their bowel frequency. Three of the @entity1 also experienced reversal of @entity1337 , including one who had complete reversal of @entity1337 . This study demonstrates that reversal of @entity1337 still occurred despite dividing the oral @entity1510 into very low doses relative to the total dose of opioid used. @entity1 using high doses of opioids appear to be the most vulnerable to the analgesic effect of oral @entity1510 .

title: Low-dose oral @entity1510 reverses opioid-induced @entity1142 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

answer: @entity1337 :: (MESH:D000699,Disease) :: ['analgesia']


abstract: BACKGROUND: Few data exist about the implementation of contemporary oral antiplatelet treatment guidelines in @entity1 with @entity1187 ( @entity1187 ) undergoing percutaneous coronary intervention (PCI). METHODS: GReek AntiPlatelet rEgistry (GRAPE), initiated on January 2012, is a prospective, observational, multicenter cohort study focusing on contemporary use of @entity3075 inhibitors. In 1434 @entity1 we evaluated appropriateness of @entity3075 selection initially and at discharge by applying an eligibility-assessing algorithm based on @entity3075 inhibitors' contraindications/specific warnings and precautions. RESULTS: Appropriate, less preferable and inappropriate @entity3075 inhibitor selections were made initially in 45.8%, 47.2% and 6.6% and at discharge in 64.1%, 29.2% and 6.6% of @entity1 , respectively. The selection of @entity1397 was most commonly less preferable, both initially (69.7%) and at discharge (75.6%). Appropriate selection of newer agents was high initially (79.2%-82.8%), with further increase as selection at discharge (89.4%-89.8%). Inappropriate selection of the newer agents was 17.2%-20.8% initially, decreasing to 10.2%-10.6% at discharge. Conditions and co-medications related to @entity548 risk, presentation with ST elevation @entity583 and the absence of reperfusion within the first 24h were the most powerful predictors of appropriate @entity3075 selection initially, whereas age >= 75 years, conditions and co-medications related to @entity548 risk and regional trends mostly affected appropriate @entity3075 selection at discharge. CONCLUSIONS: In GRAPE, adherence with the recently released guidelines on oral antiplatelet therapy was satisfactory. @entity1397 was most commonly used as a less preferable selection, while @entity3076 or ticagrelor selection was mostly appropriate. Certain factors may predict initial and at discharge guideline implementation. Clinical Trial Registration-clinicaltrials.gov Identifier: NCT01774955 http://clinicaltrials.gov/.

title: Implementation of contemporary oral antiplatelet treatment guidelines in @entity1 with XXXX undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndrome']

entities_list: @entity3076 :: ('MESH:C408153', 'Chemical') :: ['prasugrel']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['increased bleeding']

entities_list: @entity1397 :: ('MESH:C055162', 'Chemical') :: ['Clopidogrel', 'clopidogrel']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndrome']


abstract: It has been hypothesized that @entity0 risk is influenced by prenatal hormone levels. @entity4742 ( @entity4743 ), a synthetic @entity172 , was widely used by pregnant @entity1 in the 1950s and 1960s. @entity1 who took the drug have an increased risk of @entity0 , but whether risk is also increased in the daughters who were exposed in utero is less clear. We assessed the relation of prenatal @entity4743 exposure to risk of @entity0 in a cohort of @entity4743 -exposed and unexposed @entity1 followed since the 1970s by mailed questionnaires. Eighty percent of both exposed and unexposed @entity1 completed the most recent questionnaire. Self-reports of @entity0 were confirmed by pathology reports. Cox proportional hazards regression was used to compute incidence rate ratios (IRR) for prenatal @entity4743 exposure relative to no exposure. During follow-up, 102 incident cases of invasive @entity0 occurred, with 76 among @entity4743 -exposed @entity1 (98,591 @entity1 -years) and 26 among unexposed @entity1 (35,046 @entity1 -years). The overall age-adjusted IRR was 1.40 [95% confidence interval (95% CI), 0.89-2.22]. For @entity0 occurring at ages >or=40 years, the IRR was 1.91 (95% CI, 1.09-3.33) and for @entity5 occurring at ages >or=50 years, it was 3.00 (95% CI, 1.01-8.98). Control for calendar year, parity, age at first birth, and other factors did not alter the results. These results, from the first prospective study on the subject, suggest that @entity1 with prenatal exposure to @entity4743 have an increased risk of @entity0 after age 40 years. The findings support the hypothesis that prenatal hormone levels influence @entity0 risk.

title: Prenatal @entity4742 exposure and risk of XXXX .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Women', 'person']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

entities_list: @entity4742 :: ('MESH:D004054', 'Chemical') :: ['Diethylstilbestrol']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: BACKGROUND: Although mortality rates from @entity0 are declining, many @entity0 survivors will experience physical and psychological sequelae that affect their everyday lives. Few prospective studies have examined the rehabilitation needs of newly diagnosed @entity0 @entity1 , and little is known about the predictors of health-related quality of life (QOL) in this population. METHODS: Between 1987 and 1990, 227 @entity1 with early stage @entity0 participated in a prospective longitudinal study in which detailed information was collected through interviews, standardized measures of QOL and @entity458 , and clinical evaluation. Comparisons of physical and treatment-related problems were made according to type of surgical treatment. Multivariate regression analysis was performed to examine the predictors of QOL at one year after surgery. RESULTS: Physical and treatment-related problems were reported frequently one month after @entity0 surgery, and occurred with equal frequency in @entity1 receiving modified radical mastectomy or breast conservation treatment. There were no significant differences in problems reported at one year by type of surgery; however, frequently reported problems include ' @entity1183 in the @entity764 ,' 'tightness, pulling or stretching in the arm or axilla,' 'less energy or @entity1295 ,' 'difficulty in sleeping,' and 'hot flashes'. There was no relationship between the type of surgery and mood or QOL. Poorer QOL one year after surgery was significantly associated with greater mood disturbance and body image discomfort one month after surgery, as well as positive lymph node involvement. Although the majority of @entity1 experienced substantial disruptions in the physical and psychosocial dimensions of QOL post-operatively, most @entity1 recovered during the year after surgery, with only a minority (<10%) significantly worsening during that time. CONCLUSIONS: At one year after surgery, most @entity1 report high levels of functioning and QOL, with no relationship between the type of surgery and QOL. @entity1 who reported lower levels of QOL at one year after diagnosis had greater mood disturbance and poorer body image one month after surgery, as well as lower income and positive axillary nodes.

title: Quality of life in the first year after XXXX surgery: rehabilitation needs and patterns of recovery.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological distress']

entities_list: @entity764 :: ('MESH:D013898', 'Disease') :: ['chest wall or axilla']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: (1) @entity712 is diagnosed on the basis of both clinical symptoms and evaluation of cardiac function (preferably measured by echocardiography). @entity1002 is defined as a left ventricular ejection fraction (LVEF) below 40%. The drugs of choice for @entity712 are certain @entity1289 ( @entity1289 ) inhibitors, some diuretics, some betablockers, and @entity1482 . In one trial, @entity1482 greatly reduced mortality at 24 months (35%, compared with 46% on placebo, p <0.001). (2) @entity14292 , a @entity1482 derivative, is marketed for the treatment of left @entity67 in @entity712 @entity1 with recent @entity583 . (3) The EPHESUS study, a double-blind, placebo-controlled trial involving 6632 @entity1 , showed a significant reduction in the overall mortality rate among @entity1 with @entity712 and recent @entity583 treated with @entity14292 for 16 months (16.7% versus 14.4%; p = 0.008). This improvement was mainly due to a reduction in mortality during the first month of treatment. @entity14292 has not been compared with @entity1482 , although the latter was known to be effective before the EPHESUS trial was conducted. (4) Severe @entity4144 is frequent with @entity14292 , occurring in 5.5% of @entity1 . The risk of hyperkalaemia increases with @entity177 and co-administration of @entity972 -sparing diuretics, @entity1289 inhibitors, angiotensin II receptor antagonists and nonsteroidal antiinflammatory drugs. (5) In the short term, the incidence of @entity247 in @entity1 taking @entity14292 seems to be low. (6) In @entity1 who develop @entity712 after @entity583 , an indirect comparison of available data favours @entity1482 over @entity14292 (better efficacy, lower risk of @entity4144 ). (7) In France, treatment with @entity14292 is about 9 times more expensive than @entity1482 . (8) @entity1482 remains the treatment of choice for @entity1 with @entity712 and incapacitating @entity1353 despite @entity1289 inhibitor and diuretic therapy. @entity14292 may possibly be useful for @entity1 who have non severe @entity712 after recent @entity583 .

title: @entity14292 : new drug. Recent @entity583 with @entity712 : a XXXX me too.

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['Heart failure', 'chronic heart failure', 'heart failure']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['ACE', 'angiotensin-converting-enzyme']

entities_list: @entity4144 :: ('MESH:D006947', 'Disease') :: ['hyperkalemia']

entities_list: @entity14292 :: ('MESH:C414690', 'Chemical') :: ['eplerenone', 'Eplerenone']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity247 :: ('MESH:D006177', 'Disease') :: ['gynecomastia']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular dysfunction']

entities_list: @entity1482 :: ('MESH:D013148', 'Chemical') :: ['spironolactone', 'Spironolactone']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['Left ventricular dysfunction']

answer: @entity1482 :: (MESH:D013148,Chemical) :: ['spironolactone']


abstract: Small RNAs were selected from a highly degenerate library on the basis of their ability to bind tightly to @entity526 @entity9146 -tRNA synthetase (FRS). The 63 @entity377 library consisted of the acceptor stem and portions of the D and T stems of @entity526 tRNA( @entity815 ) flanking a 32 @entity377 randomized region. Because FRS binding relies on a correctly folded tRNA substrate, the selected variants from this library were expected to resemble tRNA( @entity815 ) structure. After seven cycles of selection, the RNA library bound to FRS with similar affinity to that of the @entity526 tRNA( @entity815 ), but did not show detectable aminoacylation. Fourteen FRS-specific isolates were sequenced and found to contain an anticodon stem-loop including the anticodon triplet of tRNA( @entity815 ). The tight-binding RNAs fell into two classes depending on the location of this step-loop within the sequence. The acceptor stem defined by the non-randomized sequence was also found to be essential for binding. Mutation of two residues within a common hexanucleotide sequence present in one of the classes reduced binding to FRS. Taken together, these results suggest that in order to bind RNAs tightly, FRS requires the simultaneous interaction of the anticodon stem-loop and acceptor stem, and additional sequences needed for proper folding. This approach should assist in the detection of motifs that resemble tRNA, but are too dissimilar to be identified by sequence comparison.

title: In vitro selection of small RNAs that bind to XXXX @entity9146 -tRNA synthetase.

entities_list: @entity9146 :: ('CHEBI:25987', 'Chemical') :: ['phenylalanyl']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity526 :: (562,Species) :: ['Escherichia coli']


abstract: PURPOSE: We determined the incidence of @entity5 detection by transperineal template guided mapping biopsy of the prostate in @entity1 with at least 1 previously negative transrectal ultrasound guided biopsy. MATERIALS AND METHODS: From January 2005 to January 2012 at least 1 negative transrectal ultrasound guided biopsy was done in 485 @entity1 in our clinical database before proceeding with transperineal template guided mapping biopsy. No study @entity1 had a previous @entity263 diagnosis. The incidence of @entity1 with 1, 2, or 3 or greater previous transrectal ultrasound guided biopsies was 55.3%, 25.9% and 18.8%, respectively. Transperineal template guided mapping biopsy was done in 74.8% of @entity1 for increasing or occasionally persistently increased @entity1486 , in 19.4% for atypical small acinar proliferation and in 5.8% for high grade @entity5436 . RESULTS: For the entire study population a median of 59 cores was submitted at transperineal template guided mapping biopsy. @entity5 was ultimately detected in 226 @entity1 (46.6%) using the transperineal template guided method, including 196 (86.7%) with clinically significant disease according to the Epstein criteria. The most common @entity5 detection site on transperineal template guided mapping biopsy was the anterior apex. CONCLUSIONS: Transperineal template guided mapping biopsy detected clinically significant @entity263 in a substantial proportion of @entity1 with negative transrectal ultrasound guided biopsy. This technique should be strongly considered in the context of increasing @entity1486 with failed confirmation of the tissue diagnosis.

title: Incidence and pathological features of XXXX detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate specific antigen']

entities_list: @entity5436 :: ('MESH:D019048', 'Disease') :: ['prostatic intraepithelial neoplasia']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: BACKGROUND AND OBJECTIVES: The aim of this study is to verify the evolution and involution of experimental @entity731 in @entity95 through the study of endothelial function, lipids and tissue lipid peroxidation, macro and microscopic quantification of @entity731 . METHODS: Thirty male New Zealand white @entity95 were divided into six groups (n=5): G1 normal diet; G2: @entity753 receiving 0.5% of @entity165 diet for 4 months; G3: @entity753 diet for 4 months after normal diet for more 4 months; G4: @entity753 diet for 4 months plus normal diet and @entity8671 for 1 month, G5: @entity753 diet for 4 months plus normal diet and @entity8671 for 2 months, G6: @entity753 diet for 4 months plus normal diet and @entity8671 for 4 months. @entity8671 was administered at a dosage of 5mg dissolved in 150 ml of water daily. At the end of the experiment were measured: total @entity165 (TC), @entity1674 (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), tissue @entity165 (CAO), lipid peroxidation tissue ( @entity1865 ). Endothelial function (RMAX) was studied in a segment of thoracic aorta, through curve-effect of @entity934 and @entity1854 . The amount of @entity731 was determined by measurement of the arterial lesion, through software, after staining with @entity10942 and histological staining. RESULTS: In relation the water the @entity95 drank 60-70 ml all day. It was seen significantly increase in all parameters at G2 both biochemical and tissue. In the group G3 it was seen significantly decrease in plasma lipids levels and tissue @entity165 . Treated groups G4, G5 and G6 all showed a decreased plasma lipid levels, only at G6 group it was noted a tissue @entity165 , tissue peroxidation and quantification of @entity731 , which showed a significant decrease. In relation the endothelial function only G6 improve significantly. INTERPRETATION AND CONCLUSIONS: Our findings indicated that the treatment with @entity8671 for 4 months is more efficient because improve the endothelial function significantly.

title: Evolution and involution of @entity731 and its relationship with vascular reactivity in @entity753 XXXX .

entities_list: @entity753 :: ('OMIM:143890', 'Disease') :: ['hypercholesterolemic']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity1854 :: ('MESH:D009599', 'Chemical') :: ['sodium nitroprusside']

entities_list: @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin', 'Rosuvastatin']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'aortic atherosclerosis']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity95 :: (9986,Species) :: ['rabbits']


abstract: OBJECTIVE: The purpose of this study was to determine the variation between prenatal and postnatal diagnosis of @entity299 diagnosed by both fetal center primary physicians and fetal pediatric cardiologists at a single tertiary referral center in the United States and evaluate why cases were misdiagnosed. METHODS: A retrospective review of all @entity299 identified prenatally by level II sonography at a tertiary referral fetal center between January 2006 and December 2008 was performed to include any @entity1 with a @entity299 and with a documented autopsy or neonatal follow-up. @entity299 diagnoses were classified as correct, incorrect, or incorrect but within the same spectrum of disease. Cases of correct diagnosis by primary physicians and pediatric cardiologists were compared. RESULTS: Sixty @entity1 with fetal @entity299 were identified among 8894 @entity1 who had level II sonography. The combined detection rate for fetal @entity299 for both primary physicians and pediatric cardiologists together was 81.7%. The detection rates of @entity299 were not statistically different between primary physicians and pediatric cardiologists: 77.9% (46 of 59) versus 85.0% (34 of 40; P = .3). The most common @entity299 misdiagnosed in our study population included @entity849 , @entity1757 , @entity3291 , truncus arteriosus, and @entity1498 . CONCLUSIONS: @entity299 is misdiagnosed in tertiary care centers by both pediatric cardiologists and fetal imaging specialists. We believe that this occurrence is related to multiple factors, including evolution of @entity299 , @entity7310 , associated @entity154 , decreased amniotic fluid volume, gestational age at evaluation, imaging techniques, and, most importantly, the experience of the sonographer.

title: XXXX : prenatal readings versus neonatal outcomes.

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital anomalies']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['ventricular septal defect']

entities_list: @entity849 :: ('MESH:D011666', 'Disease') :: ['pulmonic stenosis']

entities_list: @entity1498 :: ('MESH:D001017', 'Disease') :: ['coarctation of the aorta']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['Congenital heart disease', 'congenital cardiac lesions', 'cardiac abnormalities', 'heart abnormalities', 'fetal cardiac abnormality', 'congenital heart disease']

entities_list: @entity7310 :: ('MESH:C536469', 'Disease') :: ['maternal body habitus']

answer: @entity154 :: (MESH:D000013,Disease) :: ['Congenital cardiac anomalies']


abstract: Acute stress stimulates the expression and release of @entity3318 ( @entity3318 ) and @entity5463 ( @entity1831 ) from the hypothalamus, and the @entity9210 products beta-endorphin and ACTH from the anterior pituitary. These neuropeptides are also expressed in immune tissues, and it has been proposed that they may modulate immune responses to stress through paracrine mechanisms. We subjected @entity35 to restraint stress or central injection of @entity3426 to determine whether these acute stimuli can alter the expression of neuropeptides in the spleen and thymus. Restraint stress significantly increased the contents of all these neuropeptides in thymic, but not splenic, extracts. A single icv injection of @entity3426 increased contents of @entity3318 , AVP, ACTH and beta-endorphin in the spleens of both sham-operated and adrenalectomised (ADX) @entity35 . @entity3426 increased thymic contents of @entity3318 and ACTH in sham-operated @entity35 but these increases were not observed in ADX @entity35 . These results suggest that the effects of @entity3426 on neuropeptide expression in the spleen are independent of glucocorticoids, whereas @entity3426 stimulation of neuropeptide expression in the thymus is dependent on circulating glucocorticoids. There were significant correlations between increases in @entity3318 , ACTH and beta-endorphin in the spleen, and between @entity3318 and ACTH in the thymus, consistent with the suggestion that @entity3426 -induced increases in ACTH and beta-endorphin may be mediated through @entity3318 . These results provide evidence that stressors can directly influence neuropeptide expression in immune tissues. Thus stress may influence immune functions through paracrine mechanisms involving locally synthesised neuropeptides as well as through activation of the hypothalamo-pituitary-adrenal axis.

title: Effects of Acute Stress or Centrally Injected XXXX on Neuropeptide Expression in the Immune System.

entities_list: @entity5463 :: ('MESH:D001127', 'Chemical') :: ['arginine vasopressin']

entities_list: @entity3318 :: ('81648(Tax:10116)', 'Gene') :: ['CRH', 'corticotropin-releasing hormone']

answer: @entity3426 :: (24494(Tax:10116),Gene) :: ['Interleukin-1beta']


abstract: BACKGROUND- Laparoscopic surgery has been increasingly applied to @entity356 surgery. Gastrointestinal tract reconstruction totally done by laparoscopy also has been a challenge for those who developed this procedure. AIM- To describe simplified reconstruction after total or subtotal gastrectomy for @entity356 by laparoscopy and the results of its application in a series of cases. METHODS- In the last four years, 75 @entity1 were operated with @entity356 and two with @entity677 . Thirty-four were @entity1 and 43 @entity1 . The age ranged from 38 to 77 years with an average of 55 years. In two @entity1 with @entity677 a total and a subtotal gastrectomy were performed. In the other 75 @entity1 were done 21 total gastrectomies and 54 subtotal. In all @entity5 , gastrectomy with D2 lymphadenectomy was completed with at least 37 lymph nodes removed. Was used in these operations a modified laparoscopic technique proposed by the authors consisting in a latero lateral esophagojejunal anastomosis with linear stapler in TG as well in STG, and reconstruction of the digestive continuity also in the upper abdomen. RESULTS- The intraoperative and immediate postoperative course were uneventful, except for one case of @entity548 due to an opening clip, necessitating re-intervention. The operative time was 300 minutes, with no difference between total or subtotal gastrectomy. The number of lymph nodes removed varied from 28 to 69, averaging 37. Postoperative staging showed one case in T4 N2 M0; 13 in T2 N0 MO; 27 in T2 N1 M0; 24 in T3 N1 M0 and 10 in T3 N2 M0. Complication in only one case was observed on the 10th postoperative day with a small anastomotic leakage in esophagojejunal anastomose with spontaneous closure. CONCLUSION- The @entity1  s evolution with no complications, no mortality and just one small anastomotic leakage with no systemic repercussions is a strong indication of the liability and feasibility of this innovative technical method.

title: Simplified technique for reconstruction of the digestive tract after total and subtotal gastrectomy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: THE AIM: Despite potent clinical manifestation of @entity656 , its severity estimation and prognosis based on laboratory tests proves to be difficult. In general, the key role in disease diagnostics is attributed to enzymes secreted by this organ. However, this opinion doesn't find confirmation in all cases. MATERIAL AND METHODS: A-amylase, @entity1851 (a) serum concentration changes were evaluated in 60 @entity1 treated in our department because of @entity788 . Observation period was 30 days and the severity of disease was taken into account. All @entity1 were divided onto 2 groups. Group 1 contained 42 individuals who survived the 30 day observation period. Group 2 consisted of 18 @entity1 with poor prognoses, who died. All @entity1 were operated on between 15th and 30th day of treatment. Overall condition was monitored by means of Ranson and APACHE II scores. RESULTS: The decrease in alpha-amylase activity was noted in both groups; however the differences between groups lost its significance from the 5th day on. Initially, the pancreatic lipase activity was increased in both groups, but the differences showed no significance. In subsequent days of study those differences became statistically significant. On the contrary, differences between subsequent measurements appeared as late as in the fourth time point. @entity1851 serum concentrations were significantly higher in poorly prognosing @entity1 . In group 1 @entity1 these concentrations underwent a gradual normalization. In Group 2 lipoprotein (a) serum concentration increased reaching 100 mg/dL at the end of observation. CONCLUSIONS: The study shows lack of feasibility of alpha-amylase serum concentration assessment as a method of @entity39 in @entity1 with @entity788 . High level of lipase proves the existence of inflammatory reaction, but unspecific one regarding acute @entity788 . Although CRP levels change non-specifically during acute @entity788 , they are extremely high at the early stage of pancreas @entity39 . Serum level of Lp (a) increases in @entity788 along with overall @entity1 standing deterioration. Low levels of mentioned parameters do not exclude the diagnosis of most severe form of acute @entity788 .

title: [The role of selected enzymes and acute phase proteins in XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis', 'necrotizing pancreatitis']

entities_list: @entity656 :: ('MESH:D019283', 'Disease') :: ['acute necrotizing pancreatitis symptoms']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['pancreatic necrosis extent determination', 'necrosis']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'C-reactive protein, and lipoprotein']

answer: @entity788 :: (MESH:D010190,Disease) :: ['necrotizing pancreatitis']


abstract: BACKGROUND: @entity438 exhibit a loss of @entity4116 and an increase in the plasminogen activators @entity11693 ( @entity11693 ) and tissue plasminogen activator ( @entity2435 ). Because @entity11693 , @entity2435 , and plasmin have a limited proteolytic activity against @entity4116 , the role of plasminogen activators in the @entity439 is unclear. To investigate this question, we overexpressed @entity2630 ( @entity2630 ), an inhibitor of @entity2435 and @entity11693 , in a @entity35 model of @entity449 . METHODS AND RESULTS: @entity840 -to- @entity35 aortic xenografts were seeded with syngeneic Fischer 344 @entity35 smooth muscle cells retrovirally transduced with the @entity35 @entity2630 gene (LPSN group) or the vector alone (LXSN group). Some grafts were not seeded with cells (NO group). Western blots showed increased @entity2630 in grafts from the LPSN group compared with LXSN and NO groups. All grafts in the NO group (n=8) and 40% in the LXSN group @entity397 between days 4 and 14. At 4 weeks in the LXSN group, the remaining unruptured grafts (n=6) were aneurysmal (diameter increase > or =100%), whereas in the LPSN group (n=6) none of the grafts had @entity397 or were aneurysmal. @entity4116 was preserved in the LPSN group. @entity2435 , the major PA expressed in the model, was decreased in the LPSN group compared with the other groups, as determined by zymography. Quantitative zymography showed decreased levels of two matrix metalloproteinases (MMPs), a 28-kD caseinase, and activated @entity6929 in the LPSN group. CONCLUSIONS: The blockade of plasminogen activators prevents formation of @entity439 and @entity397 by inhibiting MMP activation.

title: Prevention of XXXX development and @entity397 by local overexpression of @entity2630 .

entities_list: @entity449 :: ('MESH:D001014', 'Disease') :: ['aortic aneurysm']

entities_list: @entity2630 :: ('24617(Tax:10116)', 'Gene') :: ['PAI-1', 'plasminogen activator inhibitor-1']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysmal disease']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['arterial rupture', 'ruptured']

entities_list: @entity11693 :: ('25619(Tax:10116)', 'Gene') :: ['urokinase plasminogen activator', 'u-PA']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['Arterial aneurysms']

answer: @entity439 :: (MESH:D000783,Disease) :: ['aneurysm']


abstract: PURPOSE: The pretreatment neutrophil-to-lymphocyte ratio (NLR) has been associated with @entity5 prognosis, influencing progression and chemosensitivity. We aimed to define the role of the NLR in predicting the outcomes to neoadjuvant chemotherapy (NAC) in @entity1 with @entity150 ( @entity150 ). @entity1 AND METHODS: The data from @entity1 treated with NAC and radical cystectomy for @entity150 from 2007 to 2015 at a tertiary care center were reviewed. The clinicopathologic pretreatment, including the NLR, and post-treatment predictors were documented. The NLR was evaluated as a continuous variable on uni- and multivariate analysis and dichotomized in Kaplan-Meier curves. The relationships with outcomes (progression-free survival [PFS], @entity5 -specific survival [CSS], and @entity1349 [ @entity1349 ]) were analyzed using Cox regression analysis and log-rank tests. The pathologic response (PR) included any downstaging from the baseline clinical stage to the final pathologic stage. RESULTS: Of 205 @entity1 with @entity150 , 75 underwent NAC (median follow-up, 31 months) with a 5-year PFS, CSS, and @entity1349 rate of 56%, 60%, and 52%, respectively, and a PR of 38.6%. On multivariate analysis, the PR, PFS, CSS, and @entity1349 were predicted by the NLR (hazard ratio > 0.8, 1.25, 1.27, and 1.12, respectively; P  < .05 for all). The NLR with age and clinical stage predicted the PR. A NLR threshold of 2.26 better predicted CSS (P  < .05) and @entity1349 (P  = .055). The limitations included the retrospective design and modest number of cases. CONCLUSION: We have provided initial evidence that a low NLR helps understand the value of the underlying immune system in predicting a good outcome to NAC. The NLR is a simple and accessible biomarker that is easy to implement in clinical practice. In addition to established prognosticators and newer genomic predictors, the NLR could improve therapeutic algorithms and help in decision-making regarding the need for NAC, which is currently underused, in @entity150 @entity1 .

title: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in @entity1 Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['MIBC', 'muscle invasive bladder cancer']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancer']